

Prescription Drug Technical Advisory Group

Christina McLaughlin, Health Policy Analyst, GMCB
Jeff Hochberg, President, Vermont Retail Druggists

May 13, 2020



Background

- The Board proposed the Prescription Drug Technical Advisory Group language to the House Health Care Committee on March 12, 2020.
- The Board has the authority to establish additional advisory groups as needed to carry out its duties under 18 V.S.A § 9374(e)(2).

Proposed Language



Sec. 1. GREEN MOUNTAIN CARE BOARD; PRESCRIPTION DRUG TECHNICAL ADVISORY GROUP; REPORT

(a) The Green Mountain Care Board shall establish a Prescription Drug Technical Advisory Group pursuant to 18 V.S.A. § 9374(e)(2) to provide input and recommendations on the topics described in subsection (b) to the Board through January 15, 2022. The Board shall appoint interested stakeholders with applicable subject matter expertise as appropriate.


(b) The Prescription Drug Technical Advisory Group may provide recommendations to the Board on one or more of the following topics:

- (1) models that enhance the Board's ability to analyze, monitor, or report the pricing of prescription drug products or the relationship between prescription drug pricing and consumer prescription drug costs;
- (2) the effectiveness of prescription drug initiatives on prescription drug costs; or
- (3) other mechanisms for increasing prescription drug price transparency at one or more levels of the prescription drug supply chain.

(c) The Green Mountain Care Board shall provide a report to the General Assembly on or before January 15, 2022, based on recommendations from the Prescription Drug Technical Advisory Group.

State as Health HUB

- VT needs to position itself to best obtain and evaluate accurate pharmacy data in order to effectively administer rates regarding or related to prescription drugs and Vermonters' access to them.



How data could be better utilized:

- Can be analyzed to provide “missing” information from Insurer and PBM reports to identify TRUE costs
- Give ability to incorporate prescription information into the EMR for enhanced decision making by Providers
- Expand the functionality of VPMS and other systems
- Give ability to evaluate 340B revenue and opportunities for Hospitals and FQHCs
- Evaluate Drug Formularies across Payors
- Enhance negotiations with Drug Manufacturers
- Create continual revenue stream for State

Board Discussion